Similarly, we found that PI3Ki, SHP2i and dual-inhibition reduced primary tumor growth, however only the PI3K/SHP2 co-targeting prolonged animal survival, indicating that only the combination decreased metastatic burden (Fig. 1H, Fig S2F). Here, PTPN11 is linked to neoplasm.